18/08/2023 10:19:57 AM | Source: Reuters
India`s Concord Biotech up 23% in debut, valuing it at over $1 billion
Shares of Indian biopharma company Concord Biotech climbed as much as 23.7% in their market debut on Friday, valuing it at 95.92 billion rupees ($1.15 billion).
The company, which makes active pharmaceutical ingredients, the key biologically active elements in a drug, opened at 900.05 rupees compared with its initial public offer (IPO) price of 741 rupees.
Indian benchmark indexes, the Nifty 50 and the S&P BSE Sensex, were down 0.5% each as of 10:02 a.m. IST.
($1 = 83.0800 Indian rupees)
Disclaimer:
The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references.
To Read Complete Disclaimer Click Here
Latest News
Adani Energy Solutions wins its largest-ever Rs 25,0...
CM NChandrababuNaidu invites Mittal Group to set up ...
AI can add $4.4 trillion to global economy, but digi...
Donald Trump 2.0 jitters: Sensex tanks over 1,200 po...
HCL Technologies trades higher on the BSE
MTaI Gears up for MedTekon: A Premier Dialogue on Me...
NTPC-CEB JV finalizes landmarked Tariff for large-sc...
Markets in transitional phase; moderate returns expe...
Param Renewable Energy Earns Global Recognition for ...
HDFC Mutual Fund Launches Planet Aspirations Quiz 20...
